Tildrakizumab

{
  "id": "MLC-T-ONC-017168",
  "term": "Tildrakizumab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.",
  "synonyms": [
    "immunoglobulin G1, anti-(human interleukin 23) (human-Mus musculus monoclonal heavy chain), disulfide with human-Mus musculus monoclonal light chain, dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tildrakizumab/"
}